FY2017 EPS Estimates for Acorda Therapeutics, Inc. Reduced by Analyst (ACOR)

Acorda Therapeutics, Inc. (NASDAQ:ACOR) – Stock analysts at Jefferies Group dropped their FY2017 earnings per share estimates for shares of Acorda Therapeutics in a research report issued to clients and investors on Thursday. Jefferies Group analyst M. Yee now forecasts that the biopharmaceutical company will post earnings per share of ($0.24) for the year, down from their previous estimate of ($0.17). Jefferies Group currently has a “Hold” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for Acorda Therapeutics’ Q4 2017 earnings at $0.89 EPS, Q3 2018 earnings at ($1.28) EPS, Q4 2018 earnings at ($1.35) EPS and FY2018 earnings at ($1.85) EPS.

Acorda Therapeutics (NASDAQ:ACOR) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). The company had revenue of $141.07 million for the quarter, compared to analysts’ expectations of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.04) earnings per share.

A number of other analysts have also weighed in on ACOR. HC Wainwright set a $34.00 price objective on shares of Acorda Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 14th. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $22.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, November 28th. TheStreet lowered shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a research report on Friday, November 17th. Cowen reissued a “buy” rating and set a $30.00 price target on shares of Acorda Therapeutics in a research report on Friday, November 17th. Finally, Janney Montgomery Scott set a $17.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a research report on Thursday, November 16th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Acorda Therapeutics has a consensus rating of “Hold” and a consensus price target of $21.47.

Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $21.60 on Monday. The stock has a market cap of $1,010.00, a price-to-earnings ratio of -17.85 and a beta of 1.58. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77.

In other news, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $20.53, for a total transaction of $226,856.50. Following the sale, the insider now owns 33,150 shares of the company’s stock, valued at approximately $680,569.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 7.90% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Crossmark Global Holdings Inc. acquired a new stake in shares of Acorda Therapeutics in the 3rd quarter worth $233,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Acorda Therapeutics during the 2nd quarter worth about $199,000. Municipal Employees Retirement System of Michigan increased its position in shares of Acorda Therapeutics by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 410 shares during the last quarter. Laurion Capital Management LP acquired a new stake in shares of Acorda Therapeutics during the 2nd quarter worth about $219,000. Finally, Aperio Group LLC increased its position in shares of Acorda Therapeutics by 2.7% during the 2nd quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 343 shares during the last quarter.

WARNING: “FY2017 EPS Estimates for Acorda Therapeutics, Inc. Reduced by Analyst (ACOR)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/25/fy2017-eps-estimates-for-acorda-therapeutics-inc-reduced-by-analyst-acor.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply